AureoGen Biosciences is Drug Discovery in United States that focus on platform methodologies business. Founded in 2003. They cover business area such as developer, novel chemistry, genetic platform methodology, cyclic peptide-base compound, vancomycin, ciclosporin, cancer drug, pharmaceutical company, novel approach, efficient, cost-effective modification, optimization, production, cyclic peptide compound.
2003
( 21 years old in 2024 )
Platform Methodologies
-
4717 Campus Drive
Suite 2300
Kalamazoo, MI 49008
United States
Private
developernovel chemistrygenetic platform methodologycyclic peptide-base compoundvancomycinciclosporincancer drugpharmaceutical companynovel approachefficient, cost-effective modificationoptimizationproductioncyclic peptide compound
* We use standard office opening hours in near AureoGen Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AureoGen Biosciences is Drug Discovery business from United States that founded in 2003 (21 years old in 2024), AureoGen Biosciences business is focusing on Platform Methodologies.
AureoGen Biosciences headquarter office and corporate office address is located in 4717 Campus Drive Suite 2300 Kalamazoo, MI 49008 United States.
AureoGen Biosciences was founded in United States.
In 2024, AureoGen Biosciences is currently focus on platform methodologies sector.
Above is snippet of Google Trends for "platform methodologies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AureoGen Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
